Alnylam Pharmaceuticals Inc ALNY announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran ALN AS1 for the prophylaxis of attacks in patients with acute hepatic porphyria AHP We note that Givosiran is being evaluated for the
June 02, 2017 at 06:52AM
from
No comments:
Post a Comment